Viatris Comes Out Swinging At Unsolicited Mini-Tender Offer
TRC Capital Makes Discounted Offer For Millions Of Shares
Executive Summary
TRC Capital Corporation, famed for making discounted offers to buy shares well below the SEC’s 5% threshold, has approached Viatris shareholders. The newly-formed company, like many others, has urged shareholders to say no.
You may also be interested in...
Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Viatris Swats Away Concerns Over Divestment Valuations
Viatris remains committed to completing the sale of its global biosimilars unit to Biocon Biologics, while continuing efforts to generate up to $9bn in pre-tax proceeds by the end of 2023 from divestments.
Viatris Slashes Full-Year Revenue Guidance By $800m
Viatris is committing to earlier EBITDA and free cash flow targets for 2022, although it now expects to lose a chunk of revenues for the full year amid severe and sustained foreign currency exposure.